CA
NZ
UK
AU
IND
US
Healthcare inside theNasdaqComposite in September 2026 is not one story but several running at once. At the top of the barbell sit companies already turning products into profits. At the other end sit earlier-stage names still spending to prove a market exists. Tarsus Pharmaceuticals …
● GeneDx grew exome and genomeVolume32% year over year to 30,785 results in the second quarter of 2026, reached adjustedNet Incomeof $0.4 million, and reiterated full-yearRevenueguidance of $475 million to $490 million.
● Nakamoto, formerly KindlyMD, ended its healthcare clinic operations on June 19, 2026 and now operates as aBitcointreasury holding roughly 4,467 Bitcoin valued at about $261.5 million as of the second quarter of 2026.
● Nutex Health swung to second-quarter 2026Net Incomeof $65.8 million and diluted EPS of $9.38, from a $17.7 million loss a year earlier, even asRevenuefell 13.6% to $210.8 million after a HaloMD billing-partner amendment and lower federal arbitration fees.
TheNasdaqComposite is broad enough to hold almost every Nasdaq-listed common stock, which means it also holds the small and mid-cap biotech names where the market's real drug-development risk lives. uniQure (NASDAQ:QURE), Xencor (NASDAQ:XNCR), Rani Therapeutics (NASDAQ:RANI), Pyxis Oncology (NASDAQ:PYXS) and Precision BioSciences (NASDAQ:DTIL) span …
● SpyGlass Pharma reported 12-month Phase 1/2 results showing a 34% mean reduction in intraocular pressure from its BIM-IOL glaucoma lens system, with $251.0 million in cash and runway guided through 2028.
● SELLAS Life Sciences is approaching the pre-specified 80th event in its pivotal Phase 3 REGAL trial for galinpepimut-S in acute myeloid leukemia, with roughly $138.3 million in cash as of June 30, 2026.
● Spruce Biosciences reported $96.3 million in cash as of June 30, 2026, and plans to submit aBiologicsLicense Application for TA-ERT in MPS IIIB (Sanfilippo Syndrome Type B) in the fourth quarter of 2026.
September 2026 is a useful moment to look at healthcare on theNasdaqComposite because the month bunches together the parts of the sector that rarely move on the same clock. A clinical-stage biotech is turning into a commercial one. A diagnostics company is trying to …
Biotech and health technology rarely move as one, and September 2026 is a useful reminder of why. Within theNasdaqComposite sit hundreds of life-science names spanning pre-revenue clinical bets and cash-generating device businesses, and the gap between the two ends of that spectrum has seldom …
Please wait processing your request...